Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis

@article{Elliott2004ImmunophenotypicNO,
  title={Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis},
  author={Michelle A Elliott and Animesh Pardanani and C Y Li and Ayalew Tefferi},
  journal={Leukemia},
  year={2004},
  volume={18},
  pages={1027-1029}
}
normal plasmacytoid DC number and secretion of IFN-a could be restored in imatinib responding CML patients. This may be advantageous, since leukaemic DC may not process antigen normally in CML. However, disappearance of the BCR–ABL positive DC population may be disadvantageous, since DC can then no longer present leukaemia-specific endogenously derived BCR–ABL peptides to the immune system. Further studies are required to define whether imatinib treatment may also modify BCR–ABL directed T-cell… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
5 Citations
8 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-8 of 8 references

CHIC 2 deletion , a surrogate for FIP 1 L 1 - PDGFRA fusion , occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy

  • A Pardanani, RP Ketterling, Brockman, HC Flynn, SF Paternoster, BM Shearer
  • Blood
  • 2003

fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy

  • A Pardanani, TK Kimlinger, TL Reeder, CY Li, A. Tefferi
  • Blood
  • 2003

Treatment of hypereosinophilic syndrome with imatinib mesilate

  • A Pardanani, M Elliott, T Reeder, C-Y Li, EJ Baxter, NCP Cross
  • Lancet
  • 2002

Similar Papers

Loading similar papers…